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Abstract
Human pancreatic ductal adenocarcinoma (PDAC) is a cancer with a dismal prognosis. The efficacy of PDAC
anticancer therapies is often short-lived; however, there is little information on how this disease entity so frequently
gains resistance to treatment. We adopted the concept of cancer stem cells (CSCs) to explain the mechanism of
resistance and evaluated the efficacy of a candidate anticancer drug to target these therapy-resistant CSCs. We
identified a subpopulation of cells in PDAC with CSC features that were enriched for aldehyde dehydrogenase
(ALDH), a marker expressed in certain stem/progenitor cells. These cells were also highly resistant to, and were
further enriched by, treatment with gemcitabine. Similarly, surgical specimens from PDAC patients showed that those
who had undergone preoperative chemo-radiation therapy more frequently displayed cancers with ALDH strongly
positive subpopulations compared with untreated patients. Importantly, these ALDH-high cancer cells were sensitive
to disulfiram, an ALDH inhibitor, when tested in vitro. Furthermore, in vivo xenograft studies showed that the effect of
disulfiram was additive to that of low-dose gemcitabine when applied in combination. In conclusion, human PDAC-
derived cells that express high levels of ALDH show CSC features and have a key role in the development of
resistance to anticancer therapies. Disulfiram can be used to suppress this therapy-resistant subpopulation.
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Introduction
The prognosis of patients with pancreatic ductal
adenocarcinoma (PDAC) is extremely poor. Only 10-20% of
PDACs are suitable for surgical resection at initial diagnosis,
and the tumor recurrence rate has been reported to reach up to
70-90%, even in patients who have undergone curative
resection [1]. The therapeutic options in a majority of patients
eventually become reduced to intensified chemotherapy and/or
radiation therapy [1,2]. Therefore, the treatment of PDAC is
extremely challenging because it easily gains resistance to
chemo-radiation therapy and becomes intractable.
A growing body of research supports the concept of cancer
stem cells (CSCs) or tumor-initiating cells. CSCs characterize
unique features, including the capacity for unlimited self-
renewal, long lifespan, high metastatic potential, and resistance
to chemotherapy [3,4]. Thus, CSCs have come to be
recognized as a tumor sub-population that should be vigorously
targeted [2,3,5]. But as a practical matter, the efficacies of
currently available CSC-targeting therapies are far from
satisfactory. Several studies have validated the role of CSCs in
the development of therapeutic resistance in PDACs [4], and
demonstrated that they are often resistant to the most
commonly used anticancer drugs, such as gemcitabine and 5-
fluorouracil [1,4,6].
In this study, we presumed that the concept of CSCs could
explain why the effects of standard chemotherapies are
frequently limited in patients who receive adjuvant
chemotherapy or chemo-radiation therapy [7-11]. We further
hypothesized that certain unique features of CSCs could be
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exploited to re-sensitize PDACs to anticancer treatments and
subsequently reverse the intractable nature; our attention was
drawn to aldehyde dehydrogenase (ALDH), which has been
recognized as a new CSCs marker especially as part of a
panel of stem cell markers [12-18]. Accumulating evidence
supports the idea that increased expression of ALDH is
associated with adverse prognosis in breast, lung, and prostate
cancers [15,16,18]. Adding to this list, Rasheed et al. recently
reported that ALDH1-positive pancreatic cancer cells
negatively influence the survival of PDAC patients [12].
Disulfiram (1-[diethylthiocarbamoyldisulfanyl]-N,N-diethyl-
methanethioamide) is an irreversible inhibitor of ALDH that has
been used to achieve alcohol-avoidance behavior during
treatment of alcoholics [19]. Disulfiram has gained attention as
a candidate anticancer medication and to date has been tested
for several solid tumors, such as breast cancer, melanoma,
and colorectal cancer [20-22]. Although the precise mechanism
underlying the anticancer activity of this agent has not been
fully elucidated, several significant clues have emerged [20-26].
Recently, Dalla Pozza et al. reported that the combined
treatment with gemcitabine and disulfiram with zinc ion
inhibited the xenograft tumor growth of pancreatic cancer cells
[27]. However, the direct effect of disulfiram on CSCs of
PDACs in relation to ALDH is undetermined.
In this study, we explored the relevance of ALDH expression
and CSC populations in PDAC. We compared responses to
disulfiram between tumor sub-populations with different levels
of ALDH expression and found that ALDH strongly positive
cells were sensitive to disulfiram. Our results suggest the
applicability of disulfiram as an anti-CSC agent that could
possibly improve the efficacy of standard chemotherapies
against PDAC.
Materials and Methods
Cell lines and reagents
The following human cell lines were used: CFPAC-1, MIA
PaCa-2, PANC-1, and AsPc-1 (pancreatic cancer cell lines);
hTERT-HPNE (normal pancreatic ductal epithelial cell line). All
the cell lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA).The cell lines have been
tested using AmplFLSTR identifier PCR Amplification kit
(Applied Biosystems, Foster, CA, cat. 4322288) and
authenticated by KCLB in February 2013. Disulfiram and
gemcitabine (Sigma) were used for in vitro viability and in vivo
xenograft assays.
Human tumor samples
This retrospective study was approved by the institutional
review board of Yonsei University Medical Center. Written
informed consent was obtained from each patient for storage
and use of specimen and medical information. Our inclusion
criteria defined a study population of 57 PDAC patients who
had been histologically diagnosed and operated Yonsei
University Medical Center from 2005 to 2008. Clinical
assessment was performed based on American Joint
Committee on Cancer TNM (tumor-node-metastasis)
classifications. Because stage III and IV pancreatic cancers are
unresectable according to TNM classifications [28], we
analyzed only stage II PDAC patients who received Whipple’s
operation or pylorus-preserving pancreatoduodenectomy with
lymph node dissection. For preoperative chemotherapy/CCRT,
gemcitabine was used in the majority (18/20; 90%) of patients.
Flow cytometry
All cell lines were analyzed for the expression of ALDH by
flow cytometry using an Aldefluor Kit (Aldagen, Inc.) following
the manufacturer’s instructions. For comparison of ALDH-bright
and ALDH-negative cells, CFPAC-1 cancer cells were sorted
based on the intensity of their ALDH activity measured by
FACS (fluorescence-activated cell sorting, BD FACS Aria™ II
cell sorter). Biotin-conjugated anti-CD24 and PerCP-Cy5.5 anti-
CD44 antibodies (eBioscience) were used according to an
immunophenotyping protocol included in the manual provided
by the vendor. DAPI (4', 6-diamidino-2-phenylindole) was used
to stain the nuclei of live cells. A PE Annexin V Apoptosis
Detection kit I (BD Bioscience) was used in conjugation with 7-
AAD (eBioscience) to identify early apoptotic cancer cells. For
the analysis of the LSK (lineage- Sca+ c-kit+) hematopoietic
stem cell frequency in the bone marrow from murine femur and
tibia, we used lineage (CD11b-biotin, Gr1-biotin, CD4-biotin,
CD8-biotin, B220-biotin, Ter119-biotin)-streptavidin-PerCP-
Cy5.5, PEcy7-conjugated sca-1, and APC-conjugated c-kit
antibodies (eBioscience).
Western blotting
Protein extracts were obtained from cells or tumor masses
using a protein extract solution (Pro-Prep; iNtRON) following
the manufacturer’s instructions. Antibodies used for Western
blot analysis included anti-ALDH1A1 (Abcam), GAPDH and
anti-β-actin (Sigma).
Real-time polymerase chain reaction (PCR)
Isolation of RNA and cDNA synthesis were performed
following the manufacturer’s protocol (RiboEx; iNtRON). SYBR
green-based array PCR was performed using the iQ5
Multicolor Real-Time PCR Detection System (Bio-Rad). The
sequences of the various PCR primers are available on
request. Relative mRNA expression levels were calculated
using the comparative Ct method with normalization to β-actin.
Mouse experiments
Animal care and experimental procedures were performed
with the approval of the KAIST Animal Care and Use
Committee. We used 6-week-old male Foxn1nu SCID mice for
xenograft assays (Orient Bio). Disulfiram tablets (Ind-Swift)
were dissolved in corn oil (Sigma) for oral administration via a
sonde. Gemcitabine (Sigma) was intraperitoneally injected (I.P)
for in vivo regression assays.
For measurement of disulfiram response, we divided the
xenotransplanted mice into disulfiram-treated mice (300 mg/m2,
twice-weekly, administrated via a sonde) and corn oil-treated
control mice. For measurement of the efficacy of combination
therapy with disulfiram and low-dose gemcitabine, we divided
the xenotransplanted mice into five groups as, disulfiram-only
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treated mice (300 mg/m2, twice-weekly, administrated via a
sonde), low-dose gemcitabine treated mice (40 mg/m2 body
surface area, I.P, weekly) [29], low-dose gemcitabine along
with oral disulfiram, 10-times higher dose of gemcitabine
treated mice (400 mg/m2 body surface area, weekly), and PBS-
treated control mice (I.P).
It is recommended that oral drug disulfiram is taken an initial
dose of 500 mg followed by a daily maintenance dose of 250
mg in human [30]. The dose translation from one animal
species to another using the body surface area (BSA)
normalization method is recommended [31]. According this
formula, we administered disulfiram of 300mg/m2 to mice twice
a week per oral.
Tumor volume measurements
Mice were enrolled for drug treatment when their tumors had
reached a size of at least 200 mm3. Tumor size was measured
with a caliper, and tumor volume was calculated using the
standard formula, length x width2 x 0.5 (mm3). Tumor initiation
in cancer cell-injected mice was monitored daily, and tumor
size was determined weekly for 3 to 5 weeks, as indicated.
Immunohistochemistry
Tumor xenografts were fixed in formalin, embedded in
paraffin, sectioned, and stained with hematoxylin and eosin
(H&E). Immunohistochemistry (IHC) with the anti-ALDH1A1
antibody (Abcam) was performed using a Dako Envision Kit
following the manufacturers’ instructions. We used internal
standards to define ALDH1A1 strongly positive cells when the
amplitude of signal was equal to or greater than that of normal
stem/progenitor cells located in the tumor-free region of the
same slide (Figure S1).
We performed IHC analysis of ALDH1A1 and compared
glandular differentiation with ALDH1A1 expression on the
human PDAC specimen (Figure 1A). To express the correlation
numerically, we counted ALDH1A1 strongly positive cancer
cells per total cancer cells composed of well differentiated and
poorly differentiated glands, respectively. We examined three
well differentiated and three poorly differentiated PDAC cases
of human in 10 high-power fields (X400 magnification).
Limiting-dilution analysis
To estimate the frequency of colony-formation, we diluted
CFPAC-1 cells into a single cell per well (100µL) and cultured
on 96 well plate in 5% CO2 incubator at 37°C. After two weeks,
we counted each colony outgrowth from a single cell and
calculated number of colonies out of total wells.
Viability assay
We performed viability assay by WST (water-soluble
tetrazolium salt) dye (EZ-cytox cell viability assay kit, itsBIO),
according to the vendor’s instruction. Samples were read by a
microplate reader using 450nm wavelength of absorbance. To
quantify the cell viability, we determined the average values
from triplicate or quadruplicate readings and have got standard
curve using GraphPad Prism 5 software.
Statistics
All statistical analyses were performed using GraphPad
Prism 5 software. For the analysis of cell viability and tumor
volume according to drug treatment, significant differences
between means were determined by an analysis of variance
(ANOVA) followed by t-tests. IHC and flow cytometry results
were analyzed by t-test and the ratio of tumors containing
ALDH-strongly positive cancer cells in surgically-resected
PDACs was compared by chi-square method. We compared
colony forming efficiency by an analysis of t-test. All reported
P-values are two-sided, and P-values less than 0.05 were
considered to indicate statistical significance.
Results
ALDH1 expression in a subtraction of tumorous and
non-tumorous human pancreatic tissues
Terminal ductal cells have been reported as pancreatic stem/
progenitor cells in several studies [32-34] and Rovira et al.
characterized the ALDH1 expression pattern of these cells in
mice [35]. However, the expression pattern of ALDH1 in non-
tumorous human pancreatic tissue has not been reported. We
thus examined human specimens and found that, similar to the
murine pancreas, human chronic pancreatitis exhibited
regenerative metaplasia and proliferating ductal cells which
would be the immediate progeny of the pancreatic stem/
progenitor cells [32,35] {Rovira, 2010 #96}also showed high
levels of ALDH1A1 expression (Figure 1A).
In human PDAC, ALDH1A1 expression varied among
different cells across a wide spectrum from negative to strongly
positive (Figure S1). Notably, poorly differentiated PDACs
displayed more abundant ALDH1A1 strongly positive cancer
cells than well-differentiated PDACs did (Figure 1A). Figure 1B
indicates the statistical difference in frequency of ALDH1A1
strongly positive cells between well differentiated (n=7) and
poorly differentiated (n=7) PDACs. We counted the cancer cells
in the 10 high-power fields (X400) of the representative slide
from each of PDAC specimens.
Next, we examined the surgical specimens who either
received preoperative chemotherapy/concurrent chemo-
radiation therapy (CCRT; n = 20) or not (n = 37), and searched
for the presence of ALDH1A1 strongly positive (Table S1).
These cells were identified by comparing the
ALDH1A1expression level of an individual cancer cell to that of
a normal stem/progenitor cell included in the adjacent tumor-
associated chronic pancreatitis tissue (Figure S1). We found
that the frequency of tumors that possess ALDH strongly
positive cells were higher in the patients who received
chemotherapy/CCRT prior to surgery (80.0%) when compared
with that of the patients who received surgical resection alone
(51.4%) (Figure 1C), suggesting that ALDH strongly positive
cancer cells were enriched by conventional chemotherapy/
CCRT.
Cancer cells that highly expressed ALDH display
multiple CSC features
To establish an in vitro platform, we screened one normal
human pancreatic ductal epithelial cell line (hTERT-HPNE) and
Targeting ALDH-High Therapy-Resistant Cancer Cells
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e78130
four human PDAC-derived cell lines (CFPAC-1, MIA PaCa-2,
PANC-1 and AsPc-1). We measured ALDH activity in each cell
line by flow cytometry using Aldefluor kit (Figure S2). Because
ALDH1A1 is a major product of the ALDH gene, fluorescence
intensity should positively correlate with ALDH1A1 [36]. Thus, a
subpopulation of cells highly expressing ALDH in flow
cytometry could be correspond with the ALDH1A1 strongly
positive cells observed in human PDAC specimens.
We defined three subset of cells based on their flow
cytometric distribution relative to the gating of DEAB negative
control either as ALDH-negative (cells located inside the region
gated by DEAB control), ALDH-high (cells located in the region
over DEAB control), and ALDH-bright (a subpopulation of
ALDH-high cells). In hTERT-HPNE, the ALDH highly
expressing subset constituted less than 5% of the total
population. Among the four PDAC cell lines, MIA PaCa-2
(>90% of the total population) and CFPAC-1 (approximately
50%) demonstrated abundant ALDH-high cancer cells. In
PANC-1 and AsPc-1 cells, the ratios of ALDH-high populations
were comparable to or less than that of hTERT-HPNE cells.
Consistently, ALDH1A1 protein was detected in significant
amounts in MIA PaCa-2 and CFPAC-1 cells lines, but only at
minimal levels in PANC-1 and AsPc-1 cells (Figure S2).
On the basis of previous literature [12-14,18,37] and our
observations, we inferred that ALDH-bright cancer cells might
actually represent CSCs. Previous studies have applied ALDH,
as part of a panel with other stem cell markers, to identify
normal and cancer stem cells in the pancreas [12,13,37]. We
tested whether ALDH alone can be used as a bona fide stem
cell marker and whether cells with high levels of ALDH
expression actually represented CSCs. To do this, we used
CFPAC-1 cell line because it is known that the subpopulation
Figure 1.  IHC analysis of ALDH1A1 in surgical specimens from human PDAC.  (A) IHC analysis of ALDH1A1 in surgical
specimens of human chronic pancreatitis and PDAC. Upper panels, H&E stain and lower panels, ALDH1A1 IHC stain. (B) The
frequency of ALDH1A1 strongly positive cells between well differentiated and poorly differentiated PDACs. (C) Profiles of ALDH
activity of human PDACs according to whether preoperative treatment was performed. *P < 0.05. Error bars represent standard
deviations.
doi: 10.1371/journal.pone.0078130.g001
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of CFPAC-1 is enriched with cancer stem-like cells [38] and we
found that CFPAC-1 showed evenly distributed ALDH-high and
-negative cancer cells in Aldefluor assay. We further sorted
cells based on the magnitude of their ALDH activity identified
by FACS and compared the upper and lower 5% of cells, which
we defined as ALDH-bright and ALDH-negative sub-
populations, respectively. ALDH1A1 mRNA and protein levels
were consistent with ALDH levels identified by FACS (Figure
S2).
We next analyzed CFPAC-1 cells with different levels of
ALDH for the co-expression of CD24 and CD44, which are
commonly used stem cell markers [14]. This revealed that
ALDH activity positively correlated with those of CD24 and
CD44 (Figure 2A). A limiting dilution colony-forming assay
revealed that ALDH-bright cells had greater colony-forming
activity than ALDH-negative cells (Figure 2B). We separately
cultured ALDH-bright and ALDH-negative cells, and analyzed
the ALDH activity after 2 weeks (Figure 2C). The progeny of
ALDH-bright cells included both ALDH-bright and ALDH-
negative cells; thus, ALDH-bright cells successfully re-
established the original population. In contrast, ALDH-negative
cells failed to fully recover the ALDH-bright cell population.
Another well-characterized feature of CSCs is their
resistance to chemotherapy and/or radiation-therapy [3].
Hence, we assessed the sensitivity of ALDH-bright and -
negative cancer cells to a conventional anticancer drug,
gemcitabine. ALDH-bright cancer cells were highly resistant to
gemcitabine compared with ALDH-negative cancer cells,
requiring significantly higher concentrations to kill 50% of cells
(the half maximal inhibitory concentration, IC50) (Figure 2D).
This result is compatible with those of human data that ALDH
strongly positive cancer cells were enriched by conventional
chemotherapy/CCRT (Figure 1C).
Next, we subcutaneously injected 5 x 105 FACS sorted
CFPAC-1 ADLH-bright and -negative cancer cells into the
flanks of nude mice, respectively. The ALDH-bright xenografted
cells began to form a nodule within 1 week after injection, and
by 5 weeks 60% of mice had successfully formed a nodule
(Figure 2E). However, the same number of ALDH-negative
cancer cells failed to generate any nodule, even when the
observation period was extended up to 14 weeks. ALDH-
negative cancers were able to establish tumor nodules only
when the injection number of cells was increased to 1 x 106. On
histologic examination, the xenograft nodules originated from
ALDH-bright cancer cells exhibited structures with various
degrees of differentiation, ranging from well differentiated cells
that successfully formed organized glands with a lumen to
poorly differentiated cells that barely formed abortive glandular
architectures (Figure S2). Tumor cells located within poorly
differentiated regions frequently exhibited a relatively atypical
and pleomorphic morphology and displayed bizarre nuclei
compared with those from well-differentiated areas. IHC for
ALDH1A1 showed more strongly positive cells in the solid
sheet than in well-formed glands (Figure S2), in a manner
consistent with those of human PDAC specimens (Figure 1A-
B).
These results indicated that ALDH levels is sufficient to
define a subpopulation of pancreatic cancer cells that
demonstrates poor differentiation, repopulating abilities,
resistance to gemcitabine, and greater tumorigenicity, which
are compatible with the typical features of CSCs.
ALDH-bright PDAC cells are selectively and efficiently
eliminated by disulfiram
Because we identified ALDH-bright cancer cells as highly
gemcitabine-resistant, we suspected that ALDH strongly
positive cells were responsible for chemotherapy resistance.
To selectively eliminate ALDH-bright cells, we turned to
disulfiram, which is a well-known irreversible inhibitor of ALDH
[19], and investigated the correlation between the level of
ALDH expression and disulfiram sensitivity in all four human
PDAC cell lines. We treated disulfiram and calculated IC50
values based on viability assays. We observed an inverse
correlation between the percentage of cells expressing ALDH
and IC50 values for disulfiram (Figure 3A and Figure S3).
The toxicity of chemotherapeutic agents on normal tissue is
another major consideration during anticancer treatment.
Therefore, we simulated the toxicity of disulfiram by measuring
their effects on a normal pancreatic epithelial cell line, hTERT-
HPNE (Figure S3). hTERT-HPNE cells were largely insensitive
to relatively high concentrations of disulfiram. Notably, the IC50
of disulfiram for hTERT-HPNE cells by far exceeded those of
Mia PaCa-2 and CFPAC-1 cells, indicating that a sufficiently
wide therapeutic window can be secured. In contrast to the
effects of disulfiram on MiaPaCa-2 and CFPAC-1 cells, the IC50
values of disulfiram for PANC-1 and AsPc-1 cancer cell lines
were very high, a difference that we attribute to the low
percentage of PANC-1 and AsPc-1 cells that express ALDH.
Next, we further examined the effects of disulfiram on ALDH-
bright cancer cells, by assessing ALDH levels by flow
cytometry in the remaining viable CFPAC-1 cancer cells after
treatment with disulfiram (10 μM) for 12 hours (Figure 3B).
These experiments revealed that disulfiram did not significantly
affect the ALDH-low population. To test whether the disulfiram
effect was sustained even after it had been removed, it had
been withdrawn from the media and the cells were
subsequently cultured for additional 2 weeks. Interestingly,
after disulfiram had been withdrawn, the cells failed to recover
the original tumor hierarchy and exhibited a persistent shift to
the left side of the flow cytometric distribution. Moreover,
disulfiram appeared to induce apoptotic cell death in CFPAC-1
cells, increasing the ratio of 7AAD-negative and annexin V-
positive cells that represent the populations undergoing early
apoptosis (Figure 3C and Figure S3). ALDH1A1 mRNA and
protein levels remained persistently decreased in the
repopulated cells, indicating that ALDH expression was not
restored (Figure 3D-E). Collectively, these results highlight the
potential of disulfiram to selectively and efficiently target and
eliminate CSCs that would otherwise be resistant to standard
anticancer treatments. Furthermore, we performed in vitro
colony forming assay using disulfiram-pretreated CFPAC-1
cells. As expected, disulfiram-pretreated cells formed colonies
much less frequently than control cells did (Figure S3).
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Figure 2.  ALDH strongly positive CFPAC-1 cells represent a subpopulation that shows CSC features.  (A) FACS analysis for
CD24+CD44+ CFPAC-1 cells categorized into ALDHbright, ALDHhigh and ALDHnegative groups. (B) Limiting dilution colony-forming
assays performed with FACS-sorted CFPAC‑1 cells. (C) ALDH activity measured by FACS analysis in ALDHnegative and ALDHbright
CFPAC-1 cells cultured separately for 2 weeks. (D) Assay of ALDHbright and ALDHnegative CFPAC-1 cell viability after treatment with
gemcitabine. (E) Representative image and graph comparing tumor incidence after injection of FACS-sorted ALDHbright or
ALDHnegative CFPAC-1 cells. Mice were injected with the indicated number of cells (ALDHBr, 5 x 105[n = 5]; ALDHNg, 5 x 105[n = 5];
and ALDHNg, 1 x 106 [n = 5]; ALDHBr, 1 x 106 [n = 10]) on the right flank and observed for 5 weeks. 1X105ALDHnegative cancer cells
failed to generate any nodule, even when the observation period was extended up to 14 weeks. ALDHBr, ALDH-bright and ALDHNg,
ALDH-negative. *P < 0.05 and ***P < 0.0005.
doi: 10.1371/journal.pone.0078130.g002
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Oral administration of disulfiram selectively removes
ALDH-high cancer cells and inhibits tumor growth in
combination with low-dose gemcitabine
To test the effect of disulfiram in vivo, we subcutaneously
injected mice with CFPAC-1 cancer cells and divided the
xenotransplanted mice into disulfiram-treated and corn oil-
treated control groups. Tumor growth was significantly delayed
by the administration of disulfiram (Figure 4A). IHC for
ALDH1A1 of xenograft tumors revealed that the frequency of
ALDH1A1 strongly positive cancer cells was markedly reduced
by disulfiram-treatment (Figure 4B). We counted the cancer
cells in the 10 high-power fields (X400) of the representative
slide from xenograft tumors of control (n=3) and disulfiram
treated (n=3) groups. ALDH1A1 protein levels were also
decreased in disulfiram-treated tumors (Figure 4C). A flow
cytometric analysis of the ALDH-expressing cells dissociated
Figure 3.  PDAC-derived cell lines with higher ALDH activity are more sensitive to disulfiram.  (A) IC50 of disulfiram according
to ALDH expression. (B) Aldefluor assay of ALDH activity in CFPAC-1 cells treated with disulfiram (top panels) or treated transiently
with disulfiram followed by drug withdrawal (bottom panels). (C) Flow cytometric assay for 7AAD-AnnexinV+ early apoptotic cells
after 12-hour treatment with disulfiram (10μM). (D) Representative Western blots showing ALDH1A1 protein levels in CFPAC-1
under control conditions, disulfiram-treated cells, and in transiently disulfiram-treated cells with subsequent withdrawal of disulfiram.
(E) RT-PCR and qRT-PCR measurements of ALDH1A1 mRNA expression in control and disulfiram-treated cells. *P < 0.05.
doi: 10.1371/journal.pone.0078130.g003
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from tumors revealed a shift to left of the distribution in
disulfiram-treated mice, indicating that ALDH activity was
repressed by disulfiram (Figure 4D and Figure S4). We
performed in vivo tumorigenicity assays using disulfiram-
pretreated CFPAC-1 cells. As expected, disulfiram-pretreated
cells had a tendency to generate lesser nodules when
compared with corresponding control cells (Figure S4,
P<0.05 ).
Finally, we explored for the potential benefits of combined
disulfiram and gemcitabine therapy. Several previous clinical
trials have adopted combination therapies based on low-dose
gemcitabine protocols to avoid severe toxicities [29,39-41].
Similarly, we designed a protocol that adopted low-dose
gemcitabine [29] along with oral disulfiram. Encouragingly, the
combination of low-dose gemcitabine and disulfiram efficiently
suppressed tumor growth to a degree comparable to that of a
10-times higher dose of gemcitabine (Figure 4E). Therefore,
we conclude that disulfiram not only could achieve additive/
synergistic anticancer effects during combination therapy in our
in vivo PDAC models, but would also enable a significant
reduction in the required dose of cytotoxic agents.
Discussion
The treatment of PDAC is extremely challenging, as this
tumor is frequently refractory to conventional anticancer
therapies. Most patients present with an unresectable tumor
when initially diagnosed; therefore, intensive neo-adjuvant
and/or post-operative chemotherapy/CCRT is indicated for the
majority of patients on a palliative purpose. In the current study,
Figure 4.  Comparison of in vivo therapeutic responses after treatment of mice with disulfiram and/or gemcitabine.  (A) The
growth rate of CFPAC-1 xenografts was measured and presented as percentage change in volume after treating with disulfiram
(300 mg/m2, P.O, n=4). (B) Histologic analysis and quantification comparing the frequency of ALDH1A1 strongly positive cells in
control and disulfiram-treated CFPAC-1 xenografted mice. Graph shows quantification of ALDH1A1 strongly positive cells under
X400 magnification in control and disulfiram-treated groups. (C) Representative Western blot showing ALDH1A1 protein expression
in control and disulfiram-treated tumors. (D) Aldefluor assay of ALDH activity in dissociated cancer cells retrieved from control and
disulfiram-treated CFPAC-1 xenografts. (E) Growth rate of CFPAC-1 xenografts was measured and presented as the percentage
change in volume after treatment of mice with vehicle (control), disulfiram (300 mg/m2, P.O), low-dose gemcitabine (40 mg/m2, I.P),
high-dose gemcitabine (400 mg/m2, I.P), or disulfiramand low-dose gemcitabine together (n ≥ 3). *P < 0.05, **P < 0.005, and
***P < 0.0005.
doi: 10.1371/journal.pone.0078130.g004
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we described a scenario by which PDAC becomes intractable
to anticancer treatments from the perspective of CSCs. In
combination with previous studies [12-18,37], our in vitro, in
vivo, and human study results indicate that PDAC CSCs
express significantly elevated levels of ALDH and resistance to
conventional chemotherapy.
The reason why ALDH expression is enhanced in pancreatic
stem/progenitor cells and PDAC CSCs remains unclear. ALDH
is highly expressed in primitive cells during embryogenesis and
in stem/progenitor cells in several organs including the
pancreas after birth [36]. In a similar context, we speculated
that PDAC CSCs, being a primitive form of cancer cells, might
express increased levels of ALDH protein. Multiple studies
have demonstrated that hematopoietic stem cells and cancer
cells of certain solid organs with increased expression of ALDH
protein are resistant to alkylating agents and xenobiotics,
respectively [42-47]. In this study, we newly found that ALDH
strongly positive cancer cells were more abundant in tumors
from patients who had previously received chemotherapy/
CCRT compared with those who did not receive preoperative
treatment. We believe that this observation supports our
hypothesis, that therapy-resistant, ALDH strongly positive
cancer cells can become enriched by anticancer therapy during
actual practice.
In the current study, we demonstrated that disulfiram exerts
a significant cytotoxic effect on ALDH-high cancer cells derived
from human PDAC cell lines. However, xenograft experiments
showed that disulfiram only slowed the rate of tumor growth,
and failed to achieve an actual reduction in the size of tumors.
We believe that further optimization of the protocol adopting
increased disulfiram and/or gemcitabine concentrations (but
still at lower levels than that of the full dose) could be
attempted to derive more potent anti-cancer effects. Although
disulfiram effectively suppressed the ALDH-high population of
cancer cells, the ALDH-low portion was not affected and
continued to grow. Such observations led us to conclude that
disulfiram could be used in conjunction with other conventional
chemotherapy agents to establish a combination protocol
designed to exploit the complementary actions of both:
disulfiram could suppress the ALDH-high, therapy-resistant
CSC population, while conventional anticancer agents could
target the disulfiram-insensitive, ALDH-low tumor cells in an
additive and/or synergistic manner.
This is also meaningful in that disulfiram could significantly
relieve the burden of standard chemo-radiation therapies by
reducing the required dosage of toxic chemotherapeutic agents
and harmful radiation. Blackstock et al. proposed that a
schedule of twice-weekly gemcitabine at only 4% of a full
dosage (40 mg/m2) retained significant activity when
administered concurrently with radiation in patients with
advanced PDAC [29]. Using this reduced dosage of
gemcitabine in combination with disulfiram, we demonstrated a
significant suppression of tumor growth. Myelosuppression is a
major dose-limiting toxicity of gemcitabine and it is expected to
occur more frequently following the use of gemcitabine with
classical cytostatics [4]. To assess the presence of any
potential effect on the bone marrow cells, we performed in vivo
experiments with disulfiram and/or low-dose gemcitabine. As
presented in Figure S5, the administration of disulfiram alone
or in combination with low dose gemcitabine did not induce
significant alterations on the hematopoietic stem cells.
These latter observations are particularly important because
disulfiram within therapeutic dose range is a non-cytotoxic
agent that does not fall into any category of currently used
anticancer agents, and therefore might possibly represent a
new method of anti-CSC chemotherapy. Although carbon
disulfide, a disulfiram metabolite, is responsible for the
behavioral and neurological side effects of disulfiram, most of
these presented neurological and psychiatric problems in the
case of disulfiram overdose [48]. Richard K. Fuller and Enoch
Gordis reviewed the literature on disulfiram, focusing on clinical
safety and efficacy studies of this drug alone or in combination
with other pharmacotherapeutics [49].
Therefore, we anticipate that disulfiram will be established as
a safe and effective agent for use in multi-agent and/or dose-
reduced chemotherapy regimens, even in severely
compromised patients. The fact that disulfiram was effective
when administrated orally is also encouraging, since this
feature allows physicians to design a more convenient and
flexible protocol.
In conclusion, we demonstrated that PDAC tumor cells with
enhanced expression of ALDH possess CSC features. This
characteristic not only provides a theoretical explanation for the
frequent development of resistance to anticancer treatments,
but also forms the basis of a clinically relevant therapeutic
strategy insofar as these ALDH-high cancer cells might be
effectively suppressed by disulfiram. In this latter context,
disulfiramin combination with a conventional anticancer agent
provided a safe and effective anticancer therapy in vivo in
PDAC tumor models.
Supporting Information
Table S1.  Clinical assessment and ALDH1A1 expression
profiles of 57 human PDAC cases.
(DOC)
Figure S1.  Immunohistochemical analysis of ALDH1A1 in
surgical specimens from human PDAC. Representative
photograph demonstrating ALDH1A1 negative (blue dotted
line), weakly positive (red dotted line), and strongly positive
(red arrows) cancer cells compared with cells used as a
positive internal control (blue arrows). Original magnification,
X200.
(TIF)
Figure S2.  Distinct subsets of cancer cells can be
identified in PDAC-derived cell lines based on ALDH
levels. A. ALDH activity levels in various cell lines derived from
human pancreas measured by flow cytometric analyses. B.
Representative Western blot analysis for ALDH1A1 protein in
four human PDAC cell lines. C. ALDH1A1 mRNA expression
measured by semi-quantitative and quantitative RT-PCAR,
respectively, in CFPAC-1. D. Western blot demonstrating
ALDH1A1 protein levels in CFPAC-1 cells. E.
Immunohistochemical staining for ALDH1A1 in CFPAC-1
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xenograft tumors. ALDHBr, ALDH bright, and ALDHNg, ALDH
negative. *P < 0.05.
(TIF)
Figure S3.  PDAC-derived cell lines with higher ALDH
activity are more sensitive to disulfiram. A. Viability assay in
PDAC-derived cells (left panel) and normal pancreatic ductal
cell (right panel) treated with disulfiram. B. Flow cytometric
assay for 7AAD-AnnexinV+ early apoptotic cells after 12-hour
treatment with disulfiram (10μM). C. Graphs comparing colony
forming ability of disulfiram-pretreated CFPAC-1 cells.
**P<0.005.
(TIF)
Figure S4.  A. Table comparing Aldefluor assay results
demonstrating changes in cancer cell distribution of disulfiram -
treated tumors. DSF, disulfiram. B. Graphs comparing in vivo
tumorigenicity of disulfiram-pretreated CFPAC-1 cells.
(TIF)
Figure S5.  Comparison of murine LSK population after
DSF and/or low-dose GCB administration. A. Comparison of
murine LSK population after DSF (7mg/kg, twice weekly, I.P)
administration. The x-axis indicates post-injection time. B.
Comparing LSK frequency of DSF and/or low-dose GCB
(40mg/m2, weekly, I.P) treated mouse after 2 weeks. LSK,
lineage- Sca+ c-kit+. BM, bone marrow. DSF, disulfiram. GCB,
gemcitabine.
(TIF)
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